Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMC114/RTV in Treatment-Experienced HIV-1 Infected Subjects
NCT00081588Phase 2Completed
- Sponsor
- Tibotec
- Start
- Nov 2003
- Primary completion
- Sep 2005
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of darunavir in human immunodeficiency virus infection (HIV), sponsored by Tibotec. Primary endpoints: Confirmed Virologic Response (drop in viral load >= 1 log10) at 24 weeks and Safety and Tolerability at 144 weeks. Started Nov 2003; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00081588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081588.